FDA Approves Companion Diagnostics for Prostate Cancer Drug TALZENNA

The U.S. FDA has approved FoundationOne®CDx and FoundationOne®Liquid CDx as companion diagnostics for Pfizer's TALZENNA® (talazoparib). These tools will identify patients with specific HRR gene-mutated metastatic castration-resistant prostate cancer, enabling personalized treatment. This marks the first PARP inhibitor approved for use with an existing standard of care for both BRCA and non-BRCA HRR gene-mutated mCRPC.